Skip to main content
PMC home page
Canadian Journal of Public Health = Revue Canadienne de Santé Publique logoLink to Canadian Journal of Public Health = Revue Canadienne de Santé Publique
. 2010 Jan 1;101(1):96–100. doi: 10.1007/BF03405572

Protective Vascular Treatment of Patients with Peripheral Arterial Disease: Guideline Adherence According to Year, Age and Gender

Mariane Pâquet 124,224,✉, Danielle Pilon 124,324, Jean-Pierre Tétrault 424, Nathalie Carrier 524
PMCID: PMC6973983  PMID: 20364548

Abstract

Objectives

To evaluate vasoprotective pharmacological treatment of patients with peripheral arterial disease (PAD) according to: 1) year, 2) age and 3) gender.

Methods

An observational retrospective study was conducted to evaluate the systemic vascular treatment of a population-based cohort of patients with PAD ≥50 years old, discharged from a tertiary-care teaching hospital between January 1, 1997 and December 11, 2006. Data were obtained from the Régie de l’assurance maladie du Québec. Drugs evaluated included antiplatelet agents (APs), statins (STs) and angiotensin converting enzyme inhibitors (ACEIs), and a combination of all three. Proportions of patients treated were compared according to year, age and gender using Chi-square.

Results

The mean age of the study population (5962 individuals) was 73.2 ± 9.1 years; 43.8% were women. After hospital discharge, 71.6%, 47.6%, 42.2% and 20.6% were taking respectively, an AP, statin, ACEI or all three. Protective treatment improved significantly from 1997 to 2006. Significantly more subjects 50–64 years used a statin or all three agents, compared to subjects ≥65 years (statins: 56.6% vs. 45.8%, all three: 26.2% vs. 19.5%; p<0.001). Significantly more men than women used statins (49.1% vs. 45.6%; p<0.001) and ACEIs (44.5% vs. 39.3%; p<0.001). Similarily, use of all three agents was 22.4% for men and 18.2% for women (p<0.001).

Conclusions

Although systemic vascular treatment received by patients with PAD has increased in the past years, it remains suboptimal, particularly for older patients and women. Strategies to improve adherence to treatment guidelines should be developed for these high-risk populations.

Keywords: Peripheral arterial disease, secondary prevention, guideline adherence

References

  • 1.Expert Panel on Detection EaToHBCiA. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2001;285(19):2486–97. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
  • 2.Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344(21):1608–21. doi: 10.1056/NEJM200105243442108. [DOI] [PubMed] [Google Scholar]
  • 3.Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk. Vascular Med. 1997;2(3):221–26. doi: 10.1177/1358863X9700200310. [DOI] [PubMed] [Google Scholar]
  • 4.Higgins JP, Higgins JA. Epidemiology of peripheral arterial disease in women. J Epidemiol. 2003;13(1):1–14. doi: 10.2188/jea.13.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vascular Surgery. 2007;45(6):1185–91. doi: 10.1016/j.jvs.2007.02.004. [DOI] [PubMed] [Google Scholar]
  • 6.Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110(6):738–43. doi: 10.1161/01.CIR.0000137913.26087.F0. [DOI] [PubMed] [Google Scholar]
  • 7.Zheng ZJ, Rosamond WD, Chambless LE, Nieto FJ, Barnes RW, Hutchinson RG, et al. Lower extremity arterial disease assessed by ankle-brachial index in a middle-aged population of African Americans and whites: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Prev Med. 2005;29(5Suppl1):42–49. doi: 10.1016/j.amepre.2005.07.019. [DOI] [PubMed] [Google Scholar]
  • 8.Sritara P, Sritara C, Woodward M, Wangsuphachart S, Barzi F, Hengprasith B, et al. Prevalence and risk factors of peripheral arterial disease in a selected Thai population. Angiology. 2007;58(5):572–78. doi: 10.1177/0003319707303652. [DOI] [PubMed] [Google Scholar]
  • 9.Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81(2):602–9. doi: 10.1161/01.CIR.81.2.602. [DOI] [PubMed] [Google Scholar]
  • 10.Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation. 1990;82(6):1925–31. doi: 10.1161/01.CIR.82.6.1925. [DOI] [PubMed] [Google Scholar]
  • 11.Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]
  • 12.Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC) J Vascular Surgery. 2000;31(1Pt2):S1–S296. [PubMed] [Google Scholar]
  • 13.Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–86. doi: 10.1056/NEJM199202063260605. [DOI] [PubMed] [Google Scholar]
  • 14.Abramson BL, Huckell V, Anand S, Forbes T, Gupta A, Harris K, et al. Canadian Cardiovascular Society Consensus Conference: Peripheral arterial disease - Executive summary. Can J Cardiology. 2005;21(12):997–1006. [PubMed] [Google Scholar]
  • 15.Anonymous. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6921):81–106. doi: 10.1136/bmj.308.6921.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. doi: 10.1016/S0140-6736(02)09327-3. [DOI] [PubMed] [Google Scholar]
  • 17.Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360(9326):2–3. doi: 10.1016/S0140-6736(02)09358-3. [DOI] [PubMed] [Google Scholar]
  • 18.Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–89. doi: 10.1001/jama.295.2.180. [DOI] [PubMed] [Google Scholar]
  • 19.Dunkley A, Stone M, Sayers R, Farooqi A, Khunti K. A cross sectional survey of secondary prevention measures in patients with peripheral arterial disease in primary care. Postgraduate Med J. 2007;83(983):602–5. doi: 10.1136/pgmj.2007.060806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24. doi: 10.1001/jama.286.11.1317. [DOI] [PubMed] [Google Scholar]
  • 21.McDermott MM, Hahn EA, Greenland P, Cella D, Ockene JK, Brogan D, et al. Atherosclerotic risk factor reduction in peripheral arterial disease: Results of a national physician survey. J Gen Intern Med. 2002;17(12):895–904. doi: 10.1046/j.1525-1497.2002.20307.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12(4):209–15. doi: 10.1007/s11606-006-5042-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Steingart RM, Packer M, Hamm P, Coglianese ME, Gersh B, Geltman EM, et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med. 1991;325(4):226–30. doi: 10.1056/NEJM199107253250402. [DOI] [PubMed] [Google Scholar]
  • 24.Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2002;105(14):1735–43. doi: 10.1161/01.CIR.0000013074.73995.6C. [DOI] [PubMed] [Google Scholar]
  • 25.Bowling A. Ageism in cardiology. BMJ. 1999;319(7221):1353–55. doi: 10.1136/bmj.319.7221.1353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Birkhead JS, Weston C, Lowe D. Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004–5: Observational study. BMJ. 2006;332(7553):1306–11. doi: 10.1136/bmj.38849.440914.AE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360(9346):1623–30. doi: 10.1016/S0140-6736(02)11600-X. [DOI] [PubMed] [Google Scholar]
  • 28.Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart. 2005;91(5):630–34. doi: 10.1136/hrt.2004.036723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Managed Care Pharmacy. 2008;14(3):271–80. doi: 10.18553/jmcp.2008.14.3.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol. 2003;55(6):604–8. doi: 10.1046/j.1365-2125.2003.01795.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Cournot M, Cambou JP, Quentzel S, Danchin N. Annales de Cardiologie et d’Angeiologie. 2005. Motifs de sous-utilisation des thérapeutiques de prévention secondaire chez les coronariens de plus de 70 ans. [PubMed] [Google Scholar]
  • 32.Aronow WS. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontology Series A-Biological Sciences & Medical Sciences. 2001;56(3):M138–M145. doi: 10.1093/gerona/56.3.M138. [DOI] [PubMed] [Google Scholar]
  • 33.Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14(12):711–17. doi: 10.1046/j.1525-1497.1999.02229.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Crilly M, Bundred P, Hu X, Leckey L, Johnstone F. BMC Health Serv Res. 2007. Gender differences in the clinical management of patients with angina pectoris: A cross-sectional survey in primary care. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Crilly MA, Bundred PE, Leckey LC, Johnstone FC. Gender bias in the clinical management of women with angina: Another look at the Yentl syndrome. J Women’s Health. 2008;17(3):331–42. doi: 10.1089/jwh.2007.0383. [DOI] [PubMed] [Google Scholar]
  • 36.Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: A Cleveland clinic prevention database study. J Women’s Health. 2008;17(4):515–21. doi: 10.1089/jwh.2007.0443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51(4):1149–55. doi: 10.1161/HYPERTENSIONAHA.107.107342. [DOI] [PubMed] [Google Scholar]
  • 38.Simpson CR, Wilson C, Hannaford PC, Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke. 2005;36(8):1771–75. doi: 10.1161/01.STR.0000173398.99163.9e. [DOI] [PubMed] [Google Scholar]
  • 39.Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke. 2000;31(8):1833–37. doi: 10.1161/01.STR.31.8.1833. [DOI] [PubMed] [Google Scholar]
  • 40.Kaplan RC, Tirschwell DL, Longstreth WT, Jr., Manolio TA, Heckbert SR, Lefkowitz D, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology. 2005;65(6):835–42. doi: 10.1212/01.wnl.0000176058.09848.bb. [DOI] [PubMed] [Google Scholar]
  • 41.Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48(8):999–1009. doi: 10.1016/0895-4356(94)00234-H. [DOI] [PubMed] [Google Scholar]
  • 42.Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Wahlberg E. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovascular Prevention & Rehabilitation. 2009;16(1):39–46. doi: 10.1097/HJR.0b013e32831c1383. [DOI] [PubMed] [Google Scholar]
  • 43.Statistics Canada. Age Groups and Sex for Population of Canada (2006 Census) 2006. [Google Scholar]
  • 44.Hobi A, Roy S, Vuille C, Perdrix J, Darioli R. Évolution du contrôle des facteurs de risque cardiovasculaire chez les patients coronariens de plus de 65 ans. Rev Médicale Suisse. 2006;2(56):658–63. [PubMed] [Google Scholar]
  • 45.Lovell M, Harris K, Forbes T, Twillman G, Abramson B, Criqui MH, et al. Peripheral arterial disease: Lack of awareness in Canada. Can J Cardiol. 2009;25(1):39–45. doi: 10.1016/S0828-282X(09)70021-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Canadian Journal of Public Health = Revue Canadienne de Santé Publique are provided here courtesy of Springer

RESOURCES